NIKKEI 225
26,547.05 +119.40 (+0.45%) HANG SENG
19,888.61 -10.16 (-0.05%) CRUDE OIL
109.36 -1.13 (-1.02%) GOLD FUTURES
1,803.80 -4.40 (-0.24%) DOW
32,196.66 +466.36 (+1.47%) BTC-GBP
24,177.58 -355.78 (-1.45%)
Vifor Pharma AG (0RPD.L)
| Previous close | 137.15 |
| Open | 137.40 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 135.20 - 137.40 |
| 52-week range | 135.20 - 137.40 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 8.777B |
| Beta (5Y monthly) | 1.36 |
| PE ratio (TTM) | 21.16 |
| EPS (TTM) | 6.40 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Update on the timeline for Vifor Pharma tender offer
ST. GALLEN, Switzerland, May 12, 2022--Regulatory News: CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to be in a position to close the acquisition of Vifor Pharma AG by June 2022. While some antitrust authorities have approved the transaction, some approvals are still outstanding.
- Business Wire
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
ST. GALLEN, Switzerland & STAMFORD, Conn., April 28, 2022--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005801/en/
- Business Wire
94th Vifor Pharma Group Annual General Meeting
ST. GALLEN, Switzerland, April 26, 2022--Regulatory News: At today’s 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. The Annual General Meeting was again held in accordance with the Ordinance 3 and the COVID-19 Act and has been reconfirmed in view of the current status of the tender offer launched by CSL Behring AG. Shareholders exercised their rights exclusively through the independent proxy.
